Biotech News Butler
Rhythm’s Imcivree misses Phase 3 in obesity
2 articles curated from biotech news
Focus Shifts To Rhythm’s Imcivree Hypothalamic Obesity Opportunity After Phase III Miss
Citeline - Scrip
Mar 18, 2026
Rhythm’s Imcivree fails Phase 3 rare form obesity trial
Endpoints News
Mar 17, 2026
Share:
Post
Share
Want daily biotech news like this?
Sign up free